All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
About the AML Hub
The AML Hub is an open-access online resource dedicated to providing balanced, credible, and up-to-date medical education on acute myeloid leukemia (AML). Our aim is to enhance knowledge in AML through the multichannel dissemination of global advances related to its classification, diagnosis, treatment, and management.
The AML Hub shares new data, evidence-based articles, therapy approvals, expert opinions, and international congress coverage to treatment teams and researchers around the world.
Vision
For every treatment team and researcher to have instant access to expert opinions and the latest evidence-based information in AML, to aid in treatment decisions and improve the lives of patients globally.
Mission
The AML Hub is the solution for a time-stretched HCP to easily access impactful information that expedites learning and empowers their treatment decisions. Informed by patients, curated by world leaders and endorsed by expert societies the AML Hub supports HCPs worldwide.
Partnerships
The AML Hub was founded in partnership with the European Lymphoma Institute (ELI) in 2014. ELI is comprised of a network of top European specialists in the field of lymphoma who are dedicated to research, training, and education. Together they look to define strategies to analyze and characterize lymphoma, common diagnostic procedures, and therapeutic standards, as well as to facilitate clinical and fundamental research. This leads to the advancement of lymphoma research, and works to guarantee equal access for all patients to the best possible care.
The Scientific Education Support Team
The AML Hub is brought to you by Scientific Education Support (SES). SES loves nothing more than building communities and networks to facilitate education through collaboration, ensuring that patients have access to the latest support and treatment options. The SES team takes care of the everyday management, content generation, and uploads onto the AML Hub, assisting the steering committees in keeping the site as up-to-date as possible.